Chihaya Maesawa

Chihaya Maesawa

Auto-generated profile, based on publicly available information

Chihaya Maesawa

Division of Tumor Biology, Institute for Biomedical Sciences, Iwate Medical University, Iwate, Japan

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 1995 in Japanese Journal of Cancer Research
Verified
Journal Article
Open access
PDF file
MKMasahiro Kashiwaba
Masahiro Kashiwaba
GTGen Tamura
Gen Tamura
YSYasushi Suzuki
Yasushi Suzuki
CMChihaya Maesawa
Chihaya Maesawa
SOSatoshi Ogasawara
Satoshi Ogasawara
RSRyoichi Satodate
Ryoichi Satodate
We investigated mutations of the epithelial (E)‐cadherin gene and loss of heterozygosity (LOH) at flanking loci using three microsatellite markers on the long arm of chromosome 16 in 25 ductal carcinomas of the breast. Expression of E‐cadherin was also investigated immunohistochemically. No mutations were detected in exons 6 through 9 of the E‐cadherin gene. LOH was observed more frequently (42%) at D16S402 (16q‐ter) than at D16S421 (16q22.3‐q23.1) (17%), which is located near the E‐cadherin gene. Expression of E‐cadherin was observed at the cell borders in 92% (11/12) of the tumors examined. The absence of mutations in the E‐cadherin gene and its conserved expression suggest that inactivation of E‐cadherin does not contribute significantly to the invasion or metastatic potential of ductal carcinomas of the breast. Furthermore, the high frequency of LOH at 16q‐ter suggests the existence of another tumor suppressor gene which may play a crucial role in the genesis of ductal carcinomas of the breast.

5 April 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Shuya KasaiShuya Kasai
Shuya Kasai
NANobuyuki Arakawa
Nobuyuki Arakawa
AOAyaka Okubo
Ayaka Okubo
WSWataru Shigeeda
Wataru Shigeeda
SYShinji Yasuhira
Shinji Yasuhira
CMChihaya Maesawa
Chihaya Maesawa
The KEAP1-NRF2 pathway regulates cellular redox homeostasis by transcriptional induction of genes associated with antioxidant synthesis and detoxification in response to oxidative stress. Previously, we reported that KEAP1 mutation elicits constitutive NRF2 activation and resistance to cisplatin (CDDP) and dacarbazine (DTIC) in human melanomas. The present study was conducted to clarify whether an HSP90 inhibitor, 17-AAG, efficiently eliminates melanoma with KEAP1 mutation, as the NRF2 target gene, NQO1, is a key enzyme in 17-AAG bioactivation. In melanoma and non-small cell lung carcinoma cell lines with or without KEAP1 mutations, NQO1 expression and 17-AAG sensitivity are inversely correlated. NQO1 is highly expressed in normal melanocytes and in several melanoma cell lines despite the presence of wild-type KEAP1, and the NQO1 expression is dependent on NRF2 activation. Because either CDDP or DTIC produces reactive oxygen species that activate NRF2, we determined whether these agents would sensitize NQO1-low melanoma cells to 17-AAG. Synergistic cytotoxicity of the 17-AAG and CDDP combination was detected in four out of five NQO1-low cell lines, but not in the cell line with KEAP1 mutation. These data indicate that 17-AAG could be a potential chemotherapeutic agent for melanoma with KEAP1 mutation or NQO1 expression.

19 February 2022 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
HKHirofumi Kamada
Hirofumi Kamada
SYShinji Yasuhira
Shinji Yasuhira
MSMasahiko Shibazaki
Masahiko Shibazaki
HAHiroo Amano
Hiroo Amano
CMChihaya Maesawa
Chihaya Maesawa